SYHA 1815
Alternative Names: SYHA-1815Latest Information Update: 05 Nov 2021
At a glance
- Originator CSPC Pharmaceutical Group; Shanghai Runshi Pharmaceutical
- Developer Shanghai Runshi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Jun 2021 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (PO) (NCT05105464)
- 24 Aug 2020 CSPC Pharmaceutical plans a clinical trial for Solid tumours
- 24 Aug 2020 National Medical Products Administration approved the clinical trials of SYHA 1815 for Solid tumours